ACADIA Pharmaceuticals Inc
NASDAQ:ACAD

  • LAST PRICE
    17.6600
  • TODAY'S CHANGE (%)
    0.4600 (2.6744%)
  • Bid / Lots
    17.7000/ 3
  • Ask / Lots
    17.8100/ 3
  • Open / Previous Close
    17.1000 / 17.2000
  • Day Range
    17.1000
    17.9658
  • 52 Week Range
    14.1500
    32.5900
  • Volume
    1,533,672

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ACAD
ACADIA Pharmaceuticals Inc
2.9B
22.8x
---
AZTA
Azenta Inc
2.2B
-15.9x
---
CPRX
Catalyst Pharmaceuticals Inc
2.8B
44.9x
---
VCYT
Veracyte Inc
2.9B
-49.0x
---
FOLD
Amicus Therapeutics Inc
3.3B
-31.8x
---
APLS
Apellis Pharmaceuticals Inc
3.5B
-14.7x
---
As of 2024-11-08

Company Information

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Contact Information

Headquarters
12830 El Camino Real, Suite 400SAN DIEGO, CA, United States 92130
Phone
858-558-2871
Fax
858-558-2872

Executives

Independent Chairman of the Board
Stephen Biggar
Chief Executive Officer, Director
Catherine Owen Adams
Chief Financial Officer, Executive Vice President
Mark Schneyer
Chief Operating Officer, Executive Vice President, Head of Commercial
Brendan Teehan
Executive Vice President, Company Secretary and Chief Legal Officer
Jennifer Rhodes

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.9B
Revenue (TTM)
$929.2M
Shares Outstanding
165.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.41
EPS
$0.78
Book Value
$2.62
P/E Ratio
22.8x
Price/Sales (TTM)
3.1
Price/Cash Flow (TTM)
20.3x
Operating Margin
12.08%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.